Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+1.96%
1,097.27
+21.14
+1.96%
—1,076.131,079.891,100.771,079.89——
SIXC
Communications
SIXC
Communications
SIXC
-0.52%
603.60
-3.14
-0.52%
—606.74606.74607.90602.03——
SIXE
Energy
SIXE
Energy
SIXE
+0.49%
1,254.88
+6.06
+0.49%
—1,248.821,246.371,256.321,239.08——
SIXI
Industrials
SIXI
Industrials
SIXI
+0.85%
1,739.07
+14.71
+0.85%
—1,724.361,733.021,745.751,727.76——
SIXM
Financials
SIXM
Financials
SIXM
+0.04%
635.82
+0.23
+0.04%
—635.59635.08637.89633.31——
SIXR
Staples
SIXR
Staples
SIXR
+0.97%
851.33
+8.18
+0.97%
—843.15842.50851.29840.85——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.35%
217.05
+0.76
+0.35%
—216.29216.29217.04215.24——
SIXT
Technology
SIXT
Technology
SIXT
+2.36%
3,340.41
+77.00
+2.36%
—3,263.413,296.253,343.203,295.42——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.86%
947.31
+8.07
+0.86%
—939.24941.57948.11939.87——
SIXV
Health care
SIXV
Health care
SIXV
+0.37%
1,467.97
+5.41
+0.37%
—1,462.561,465.031,471.261,459.66——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.51%
2,392.54
+12.14
+0.51%
—2,380.402,394.922,412.132,386.94——
S090:FRA
Sutro Biopharma Inc
€25.40
0.00%
(0.00) 1D
Apr 28, 3:25:01 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for S090...
Mkt. cap
619.47M
Avg. vol.
5.00
Volume
0.00
52-wk high
€30.40
52-wk low
€6.53
No. of employees
137
News stories
From sources across the web
Profile
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009. Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers. Wikipedia
About Sutro Biopharma Inc
CEO-
Employees137
Founded2003
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitesutrobio.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
17.40M
63.74M
9.69M
11.65M
Cost of goods sold
51.60M
38.32M
39.85M
36.64M
Cost of revenue
51.60M
38.32M
39.85M
36.64M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.27M
10.34M
8.74M
8.66M
Operating expense
13.27M
10.34M
8.74M
8.66M
Total operating expenses
64.87M
48.67M
48.59M
45.30M
Operating income
-47.47M
15.08M
-38.90M
-33.66M
Other non operating income
-
-
-
-
EBT including unusual items
-75.97M
-11.52M
-56.86M
-46.84M
EBT excluding unusual items
-54.92M
6.90M
-47.30M
-42.45M
Income tax expense
-
-18.00K
-
-82.00K
Effective tax rate
-
0.16%
-
0.17%
Other operating expenses
-
-
-
-
Net income
-75.97M
-11.50M
-56.86M
-46.76M
Net profit margin
-436.62%
-18.04%
-586.58%
-401.49%
Earnings per share
-8.02
-1.40
-5.57
-4.88
Interest and investment income
3.19M
2.52M
2.01M
1.53M
Interest expense
-10.64M
-10.69M
-10.41M
-10.33M
Net interest expenses
-7.45M
-8.17M
-8.40M
-8.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
-45.57M
16.98M
-37.00M
-32.03M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer